Company Description
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products.
The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name.
The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments.
The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products.
The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen.
Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
| Country | Ireland |
| Founded | 1949 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 95,000 |
| CEO | Geoffrey Martha |
Contact Details
Address: Building Two, Parkmore Business Park West Galway Ireland | |
| Phone | 353 1 438 1700 |
| Website | medtronic.com |
Stock Details
| Ticker Symbol | MDT |
| Exchange | NYSE |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0001613103 |
| CUSIP Number | G5960L103 |
| ISIN Number | IE00BTN1Y115 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Geoffrey Straub Martha | Chairman of the Board and Chief Executive Officer |
| Thierry Pieton | Executive Vice President and Chief Financial Officer |
| Gary Corona | Senior Vice President of Corporate Finance |
| Brett A. Wall | Executive Vice President and President of Neuroscience Portfolio |
| Gregory L. Smith | Executive Vice President of Enterprise Operations |
| Mark Ploof | Senior Vice President of Global Operations and Business Services |
| Denise L. Blomquist | Vice President, Global Controller and Chief Accounting Officer |
| Dr. Kenneth E. Washington Ph.D. | Senior Vice President and Chief Technology and Innovation Officer |
| Dr. Laura Mauri M.D., M.Sc. | Senior Vice President and Chief Scientific and Medical Officer |
| Ryan Weispfenning | Vice President and Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 4, 2025 | ARS | Filing |
| Sep 3, 2025 | 144 | Filing |
| Aug 26, 2025 | 10-Q | Quarterly Report |
| Aug 26, 2025 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| Aug 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 25, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 19, 2025 | 8-K | Current Report |
| Aug 5, 2025 | PRE 14A | Other preliminary proxy statements |
| Jul 2, 2025 | 25-NSE | Filing |
| Jun 23, 2025 | 8-K | Current Report |